XMD 8-92 is an ERK5 (BMK1) and BRD4 inhibitor (K d of 80 and 190 nM, respectively). Selective for 402 different kinases, also inhibits DCAMKL2, PLK4 and TNK1 (Kd values of 190, 600 and 890 nM). XMD 8-92 has been shown to block growth factor-induced cellular BMK1 activation and reduce BMK1 activity in in vitro kinase assays. XMD 8-92 reduces the BMK1-dependent transactivation activity of MEF2C. Blocks tumor cell proliferation and tumor-associated angiogenesis.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.